Qiagen N.V.

NYSE:QGEN 株式レポート

時価総額：US$9.3b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Qiagen 過去の業績

過去 基準チェック /26

Qiagenは、平均年間27.1%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間 成長しています。収益は、平均年間16.8% 6.6%収益成長率で 成長しています。 Qiagenの自己資本利益率は9.4%であり、純利益率は17.4%です。

主要情報

27.1%

収益成長率

27.1%

EPS成長率

Life Sciences 業界の成長21.5%
収益成長率6.6%
株主資本利益率9.4%
ネット・マージン17.4%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

May 21
With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03
Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Mar 20
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04
A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31
We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Aug 25
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Jul 28
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio

Jul 15

Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Jun 29
Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

May 26
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) A Risky Investment?

Apr 29
Is Qiagen (NYSE:QGEN) A Risky Investment?

収支内訳

Qiagen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NYSE:QGEN 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 241,939337570195
31 Dec 231,965341579199
30 Sep 231,956485600188
30 Jun 231,979490606189
31 Mar 231,999353599198
31 Dec 222,142423604190
30 Sep 222,226488618178
30 Jun 222,261539616177
31 Mar 222,313563606180
31 Dec 212,252513584190
30 Sep 212,240311604184
30 Jun 212,190480572182
31 Mar 212,065449549162
31 Dec 201,870359525149
30 Sep 201,713191522137
30 Jun 201,61214517142
31 Mar 201,550-31530151
31 Dec 191,526-41530157
30 Sep 191,516-25502164
30 Jun 191,511196492164
31 Mar 191,507188508163
31 Dec 181,502190497162
30 Sep 181,49690476162
30 Jun 181,48278474158
31 Mar 181,45355466157
31 Dec 171,41840478154
30 Sep 171,38789467145
30 Jun 171,36275480143
31 Mar 171,34782480147
31 Dec 161,33880470150
30 Sep 161,320123485157
30 Jun 161,296123471157
31 Mar 161,281126450148
31 Dec 151,281130445147
30 Sep 151,293104475151
30 Jun 151,315105484157
31 Mar 151,326113487162
31 Dec 141,345116490164
30 Sep 141,345151487163
30 Jun 141,331157487156
31 Mar 141,31572487152
31 Dec 131,30269486146
30 Sep 131,28744498112
30 Jun 131,27032512108

質の高い収益: QGENは 高品質の収益 を持っています。

利益率の向上: QGENの現在の純利益率 (17.4%)は、昨年(17.7%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: QGENの収益は過去 5 年間で年間27.1%増加しました。

成長の加速: QGENは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: QGENは過去 1 年間で収益成長率がマイナス ( -4.5% ) となったため、 Life Sciences業界平均 ( -6.5% ) と比較することが困難です。

株主資本利益率

高いROE: QGENの 自己資本利益率 ( 9.4% ) は 低い とみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y